Cargando…

Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update

With the aging of the population, malignancies are becoming common complications in patients with rheumatoid arthritis (RA), particularly in elderly patients. Such malignancies often interfere with RA treatment. Among several therapeutic agents, immune checkpoint inhibitors (ICIs) which antagonize i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dang, Quang Minh, Watanabe, Ryu, Shiomi, Mayu, Fukumoto, Kazuo, Nobashi, Tomomi W., Okano, Tadashi, Yamada, Shinsuke, Hashimoto, Motomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051463/ https://www.ncbi.nlm.nih.gov/pubmed/36982715 http://dx.doi.org/10.3390/ijms24065643

Ejemplares similares

Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems
por: Watanabe, Ryu, et al.
Publicado: (2022)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
por: Bobircă, Anca, et al.
Publicado: (2021)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
por: Ceeraz, Sabrina, et al.
Publicado: (2014)

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2020)

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
por: Lee, Kyung-Ann, et al.
Publicado: (2019)

Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
por: Steven, Neil M, et al.
Publicado: (2019)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases
por: Gerasimova, Elena V., et al.
Publicado: (2022)

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
por: Yamada, Kentaro, et al.
Publicado: (2021)

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Komiya, Kazutoshi, et al.
Publicado: (2019)

Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature
por: Benfaremo, Devis, et al.
Publicado: (2018)

Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
por: Calabrese, C, et al.
Publicado: (2017)

Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis
por: Zhang, Shuo, et al.
Publicado: (2021)

Correction: Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
Publicado: (2017)

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
por: Kostine, Marie, et al.
Publicado: (2021)

Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis
por: Verspohl, Sophia H., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Management of the Adverse Effects of Immune Checkpoint Inhibitors
por: Morgado, Manuel, et al.
Publicado: (2020)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
por: Paluri, Ravi Kumar, et al.
Publicado: (2023)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Calprotectin in Patients with Rheumatic Immunomediated Adverse Effects Induced by Checkpoints Inhibitors
por: Frade-Sosa, Beatriz, et al.
Publicado: (2023)

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
por: Kato, Koki, et al.
Publicado: (2022)

Peripheral lymphocyte fluctuation as an indicator of severe immune‐related adverse events in patients treated with immune checkpoint inhibitors
por: Haraguchi, Masafumi, et al.
Publicado: (2023)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Choi, Juwhan, et al.
Publicado: (2020)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c7oc2hvf9pit1dh1jjcpe6fltu